back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-06-05 11:47 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-553,744 vol |
0 | |
| Filed 2024-06-05 11:47 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$-6,300
-300 vol $21.00 each |
0 | |
| Filed 2024-06-05 11:41 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-63,700 vol |
0 | |
| Filed 2024-06-05 11:41 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-574,100 vol |
0 | |
| Filed 2024-06-05 11:40 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$-251,097
-11,957 vol $21.00 each |
0 | |
| Filed 2024-06-05 11:38 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-63,700 vol |
0 | |
| Filed 2024-06-05 11:38 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-232,268 vol |
0 | |
| Filed 2024-06-05 11:37 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-119,651 vol |
0 | |
| Filed 2024-06-05 11:37 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-955,544 vol |
0 | |
| Filed 2024-06-05 11:36 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Eric Burak (Indirect Ownership)
|
Non-Voting Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-38,490 vol |
0 | |
| Filed 2024-06-05 11:33 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bobilev, Dmitri
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-91,000 vol |
0 | |
| Filed 2024-06-05 11:33 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bobilev, Dmitri
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-701,700 vol |
0 | |
| Filed 2024-06-05 11:16 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-318,147 vol |
0 | |
| Filed 2024-06-05 11:15 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-192,200 vol |
0 | |
| Filed 2024-06-05 11:15 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-1,139,816 vol |
0 | |
| Filed 2024-06-05 11:14 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-443,828 vol |
0 | |
| Filed 2024-06-05 11:14 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-2,142,489 vol |
0 | |
| Filed 2024-06-05 11:09 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-81,300 vol |
0 | |
| Filed 2024-06-05 11:08 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-770,400 vol |
0 | |
| Filed 2024-06-05 11:08 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$-269,703
-12,843 vol $21.00 each |
0 | |
| Filed 2024-06-05 11:03 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-63,700 vol |
0 | |
| Filed 2024-06-05 11:03 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-1,100,844 vol |
0 | |
| Filed 2024-06-05 11:02 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
$-136,500
-6,500 vol $21.00 each |
0 | |
| Filed 2024-06-05 10:58 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Meek, Jr., David Dunlap
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-34,000 vol |
0 | |
| Filed 2024-06-05 10:34 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lee, Philina
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-81,000 vol |
0 | |
| Filed 2024-06-05 10:33 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lamb, Damian Peter
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-30,000 vol |
||
| Filed 2024-06-05 10:30 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lamb, Damian Peter
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-30,000 vol |
||
| Filed 2024-06-05 10:26 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Gannon, Steven Richard
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-141,011 vol |
0 | |
| Filed 2024-06-05 10:26 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Gannon, Steven Richard
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-81,000 vol |
0 | |
| Filed 2024-06-05 10:21 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Duncan, Barbara
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-81,000 vol |
0 | |
| Filed 2024-06-05 10:17 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Cagnoni, Pablo Jorge
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-141,011 vol |
0 | |
| Filed 2024-06-05 10:17 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Cagnoni, Pablo Jorge
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-81,000 vol |
0 | |
| Filed 2024-06-05 10:14 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bitetti, Teresa Marie
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-34,000 vol |
0 | |
| Filed 2024-06-05 10:11 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bergstrom, Donald Alan
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-85,000 vol |
0 | |
| Filed 2024-06-05 10:07 Tx date 2024-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bender, Jeremy
4 - Director of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
-34,000 vol |
0 | |
| Filed 2024-03-12 15:42 Tx date 2022-02-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+55,194 vol |
334,900 | |
| Filed 2024-03-12 15:40 Tx date 2022-02-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+22,706 vol |
279,706 | |
| Filed 2024-03-12 15:36 Tx date 2022-02-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+406,600 vol |
1,322,089 | |
| Filed 2024-03-12 15:33 Tx date 2022-02-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+11,059 vol |
744,744 | |
| Filed 2024-03-12 15:33 Tx date 2022-02-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+155,941 vol |
733,685 | |
| Filed 2024-03-12 15:31 Tx date 2022-02-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+168,200 vol |
599,444 | |
| Filed 2024-01-05 12:17 Tx date 2023-08-31 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
+12,843 vol |
12,843 | |
| Filed 2024-01-05 12:16 Tx date 2021-09-27 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-01-05 12:15 Tx date 2023-08-31 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
+11,957 vol |
11,957 | |
| Filed 2024-01-05 12:14 Tx date 2021-11-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-01-05 12:12 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
56 - Grant of rights
|
+63,700 vol |
63,700 | |
| Filed 2024-01-05 12:12 Tx date 2021-11-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-01-05 12:12 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+106,100 vol |
574,100 | |
| Filed 2024-01-05 12:10 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
56 - Grant of rights
|
+63,700 vol |
63,700 | |
| Filed 2024-01-05 12:10 Tx date 2020-06-25 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-01-05 12:10 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+106,100 vol |
933,844 | |
| Filed 2024-01-05 12:05 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
56 - Grant of rights
|
+63,700 vol |
63,700 | |
| Filed 2024-01-05 12:05 Tx date 2020-06-25 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-01-05 12:04 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+106,100 vol |
787,344 | |
| Filed 2024-01-05 12:03 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
56 - Grant of rights
|
+81,300 vol |
81,300 | |
| Filed 2024-01-05 12:02 Tx date 2021-09-27 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-01-05 12:02 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+135,500 vol |
692,500 | |
| Filed 2024-01-05 12:00 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bobilev, Dmitri
5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
56 - Grant of rights
|
+91,000 vol |
91,000 | |
| Filed 2024-01-05 11:57 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
56 - Grant of rights
|
+192,200 vol |
192,200 | |
| Filed 2024-01-05 11:56 Tx date 2020-06-25 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Rights Restricted Stock Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-01-05 11:56 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+320,400 vol |
1,735,889 | |
| Filed 2024-01-05 11:53 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+320,400 vol |
||
| Filed 2024-01-05 11:52 Tx date 2024-01-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+320,400 vol |
||
| Filed 2023-06-14 17:43 Tx date 2023-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Preston, Heather Elizabeth
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
81,000 | |
| Filed 2023-06-14 17:42 Tx date 2023-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lee, Philina
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
81,000 | |
| Filed 2023-06-14 17:41 Tx date 2023-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Khuong, Chau Quang
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
81,000 | |
| Filed 2023-06-14 17:39 Tx date 2023-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Gannon, Steven Richard
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
81,000 | |
| Filed 2023-06-14 17:38 Tx date 2023-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Duncan, Barbara
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
81,000 | |
| Filed 2023-06-14 17:36 Tx date 2023-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Cagnoni, Pablo Jorge
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
81,000 | |
| Filed 2023-06-14 17:34 Tx date 2023-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bergstrom, Donald Alan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
85,000 | |
| Filed 2023-01-09 09:12 Tx date 2023-01-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
1,415,489 | |
| Filed 2023-01-09 09:12 Tx date 2023-01-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
||
| Filed 2023-01-09 09:11 Tx date 2023-01-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
||
| Filed 2023-01-09 09:10 Tx date 2023-01-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+300,000 vol |
557,000 | |
| Filed 2023-01-09 09:08 Tx date 2023-01-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
468,000 | |
| Filed 2023-01-09 09:06 Tx date 2023-01-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
827,744 | |
| Filed 2023-01-09 09:02 Tx date 2023-01-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+250,000 vol |
681,244 | |
| Filed 2022-11-14 09:25 Tx date 2022-11-11 |
$FUSN
Fusion Pharmaceuticals Inc. |
Khuong, Chau Quang
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$100,181
+42,093 vol $2.38 each |
42,093 | |
| Filed 2022-11-14 09:24 Tx date 2020-06-25 |
$FUSN
Fusion Pharmaceuticals Inc. |
Khuong, Chau Quang
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-11-08 08:59 Tx date 2022-11-07 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bobilev, Dmitri
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+550,000 vol |
550,000 | |
| Filed 2022-11-08 08:57 Tx date 2022-11-07 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bobilev, Dmitri
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-06-22 22:08 Tx date 2022-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Preston, Heather Elizabeth
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
64,000 | |
| Filed 2022-06-22 22:06 Tx date 2022-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lee, Philina
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
64,000 | |
| Filed 2022-06-22 22:04 Tx date 2022-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Khuong, Chau Quang
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
64,000 | |
| Filed 2022-06-22 22:03 Tx date 2022-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Gannon, Steven Richard
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
64,000 | |
| Filed 2022-06-22 22:01 Tx date 2022-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Duncan, Barbara
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
64,000 | |
| Filed 2022-06-22 22:00 Tx date 2022-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Cagnoni, Pablo Jorge
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
64,000 | |
| Filed 2022-06-22 21:58 Tx date 2022-06-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bergstrom, Donald Alan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
68,000 | |
| Filed 2022-04-29 09:14 Tx date 2022-04-27 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-27,201.33
-4,511 vol $6.03 each |
318,147 | |
| Filed 2022-04-26 16:45 Tx date 2022-04-26 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-13,032.29
-2,147 vol $6.07 each |
322,658 | |
| Filed 2022-04-26 16:44 Tx date 2022-04-25 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-12,277.08
-2,036 vol $6.03 each |
324,805 | |
| Filed 2022-04-21 17:00 Tx date 2022-04-21 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-5,541.22
-922 vol $6.01 each |
326,841 | |
| Filed 2022-04-21 08:18 Tx date 2022-04-20 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-2,209.34
-367 vol $6.02 each |
327,763 | |
| Filed 2022-04-18 16:00 Tx date 2022-04-13 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-76,881.54
-11,994 vol $6.41 each |
328,130 | |
| Filed 2022-04-13 11:27 Tx date 2022-04-12 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-129,610.50
-18,255 vol $7.10 each |
340,124 | |
| Filed 2022-04-13 11:27 Tx date 2022-04-11 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-19,162
-2,600 vol $7.37 each |
358,379 | |
| Filed 2022-04-08 18:31 Tx date 2022-04-08 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-6,211.52
-826 vol $7.52 each |
360,979 | |
| Filed 2022-04-07 23:40 Tx date 2022-04-07 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-9,487.80
-1,255 vol $7.56 each |
361,805 | |
| Filed 2022-04-07 23:40 Tx date 2022-04-06 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-758.00
-100 vol $7.58 each |
363,060 | |
| Filed 2022-04-07 23:39 Tx date 2022-04-05 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-16,107
-2,100 vol $7.67 each |
363,160 | |
| Filed 2022-04-04 16:40 Tx date 2022-04-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-5,467
-700 vol $7.81 each |
365,260 | |
| Filed 2022-04-04 16:39 Tx date 2022-04-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-7,750
-1,000 vol $7.75 each |
365,960 | |
| Filed 2022-03-30 22:28 Tx date 2022-03-30 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-2,256
-300 vol $7.52 each |
366,960 | |
| Filed 2022-03-30 22:28 Tx date 2022-03-29 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-1,504
-200 vol $7.52 each |
367,260 | |
| Filed 2022-03-28 17:18 Tx date 2022-03-28 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-72,480
-9,600 vol $7.55 each |
367,460 | |
| Filed 2022-03-28 17:18 Tx date 2022-03-25 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-3,710
-500 vol $7.42 each |
377,060 | |
| Filed 2022-03-25 16:17 Tx date 2022-03-24 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-5,222
-700 vol $7.46 each |
377,560 | |
| Filed 2022-03-25 16:16 Tx date 2022-03-23 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-750.00
-100 vol $7.50 each |
378,260 | |
| Filed 2022-03-22 16:54 Tx date 2022-03-22 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-30,120
-4,000 vol $7.53 each |
378,360 | |
| Filed 2022-03-22 09:33 Tx date 2022-03-21 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-11,205
-1,500 vol $7.47 each |
382,360 | |
| Filed 2022-03-18 17:49 Tx date 2022-03-18 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-9,162.44
-1,204 vol $7.61 each |
383,860 | |
| Filed 2022-03-18 10:58 Tx date 2022-03-17 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-6,759
-900 vol $7.51 each |
385,064 | |
| Filed 2022-03-16 23:05 Tx date 2022-03-16 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-699.00
-100 vol $6.99 each |
385,964 | |
| Filed 2022-03-16 23:05 Tx date 2022-03-15 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-712.00
-100 vol $7.12 each |
386,064 | |
| Filed 2022-03-16 23:04 Tx date 2022-03-14 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-9,048
-1,300 vol $6.96 each |
386,164 | |
| Filed 2022-03-16 23:04 Tx date 2022-03-11 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-713.00
-100 vol $7.13 each |
387,464 | |
| Filed 2022-03-16 23:04 Tx date 2022-03-10 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-13,414
-1,900 vol $7.06 each |
387,564 | |
| Filed 2022-03-16 23:03 Tx date 2022-03-09 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-5,704.68
-822 vol $6.94 each |
389,464 | |
| Filed 2022-03-16 22:59 Tx date 2022-03-08 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-20,787.68
-3,004 vol $6.92 each |
390,286 | |
| Filed 2022-03-16 22:59 Tx date 2022-03-07 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-21,669
-3,100 vol $6.99 each |
393,290 | |
| Filed 2022-03-16 22:58 Tx date 2022-03-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-61,488
-8,400 vol $7.32 each |
396,390 | |
| Filed 2022-03-16 22:58 Tx date 2022-03-03 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-1,456
-200 vol $7.28 each |
404,790 | |
| Filed 2022-03-16 22:58 Tx date 2022-03-02 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-197,502.24
-26,546 vol $7.44 each |
404,990 | |
| Filed 2022-03-16 22:57 Tx date 2022-03-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-6,242.39
-847 vol $7.37 each |
431,536 | |
| Filed 2022-03-16 22:57 Tx date 2022-02-28 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-22,940
-3,100 vol $7.40 each |
432,383 | |
| Filed 2022-03-16 22:57 Tx date 2022-02-25 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-61,710.64
-8,152 vol $7.57 each |
435,483 | |
| Filed 2022-03-16 22:56 Tx date 2022-02-24 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-18,525
-2,500 vol $7.41 each |
443,635 | |
| Filed 2022-03-16 22:56 Tx date 2022-02-23 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-227,653.23
-29,299 vol $7.77 each |
446,135 | |
| Filed 2022-03-16 22:55 Tx date 2022-02-22 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-32,185
-4,100 vol $7.85 each |
475,434 | |
| Filed 2022-03-16 22:55 Tx date 2022-02-18 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-38,596.24
-4,898 vol $7.88 each |
479,534 | |
| Filed 2022-03-16 22:55 Tx date 2022-02-17 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-13,566
-1,700 vol $7.98 each |
484,432 | |
| Filed 2022-03-16 22:54 Tx date 2022-02-16 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-265,283.98
-33,202 vol $7.99 each |
486,132 | |
| Filed 2022-03-16 22:54 Tx date 2022-02-15 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Centre for Probe Development and Commercialization in trust for Valliant Consulting & Management Inc. (Indirect Ownership)
|
Voting Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-104,958
-12,600 vol $8.33 each |
519,334 | |
| Filed 2021-11-02 13:37 Tx date 2021-11-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+218,000 vol |
218,000 | |
| Filed 2021-11-02 13:36 Tx date 2021-11-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Leamon, Christopher Paul
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-10-12 09:39 Tx date 2021-09-27 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+257,000 vol |
257,000 | |
| Filed 2021-10-12 09:37 Tx date 2021-09-27 |
$FUSN
Fusion Pharmaceuticals Inc. |
Rawat, Mohit
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-06-07 16:58 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Preston, Heather Elizabeth
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
47,000 | |
| Filed 2021-06-07 16:57 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lee, Philina
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
47,000 | |
| Filed 2021-06-07 16:53 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Khuong, Chau Quang
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
47,000 | |
| Filed 2021-06-07 16:50 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Gannon, Steven Richard
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
47,000 | |
| Filed 2021-06-07 16:49 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Cagnoni, Pablo Jorge
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
47,000 | |
| Filed 2021-06-07 16:48 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Cagnoni, Pablo Jorge
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
||
| Filed 2021-06-07 16:47 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Duncan, Barbara
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
47,000 | |
| Filed 2021-06-07 16:46 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Cagnoni, Pablo Jorge
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
||
| Filed 2021-06-07 16:44 Tx date 2021-06-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bergstrom, Donald Alan
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+17,000 vol |
51,000 | |
| Filed 2021-04-05 16:24 Tx date 2021-04-01 |
$FUSN
Fusion Pharmaceuticals Inc. |
Bergstrom, Donald Alan
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
34,000 | ||
| Filed 2021-02-12 11:50 Tx date 2021-02-11 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lee, Philina
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+30,000 vol |
30,000 | |
| Filed 2021-02-12 11:48 Tx date 2021-02-11 |
$FUSN
Fusion Pharmaceuticals Inc. |
Lee, Philina
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-02-08 19:03 Tx date 2021-02-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+136,600 vol |
431,244 | |
| Filed 2021-02-08 19:02 Tx date 2021-02-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+41,000 vol |
294,644 | |
| Filed 2021-02-08 19:00 Tx date 2021-02-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Burak, Eric Steven
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+139,000 vol |
253,644 | |
| Filed 2021-02-08 18:56 Tx date 2021-02-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
O'Leary, James John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+114,000 vol |
553,744 | |
| Filed 2021-02-08 18:51 Tx date 2021-02-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Crowley, John Joseph
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+138,000 vol |
577,744 | |
| Filed 2021-02-08 18:46 Tx date 2021-02-04 |
$FUSN
Fusion Pharmaceuticals Inc. |
Valliant, John Fitzmaurice
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+336,000 vol |
915,489 | |
| Filed 2020-11-03 15:02 Tx date 2020-10-30 |
$FUSN
Fusion Pharmaceuticals Inc. |
Duncan, Barbara
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
30,000 |